Macrovascular disease in diabetes: Current status

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Roesen, P ^a   Ferber, P ^a   Tschoepe, D ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Endothelial dysfunction; Inflammation; Platelets; Prethrombotic state; Vascular candidate genes

Indexed keywords

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; HIGH RISK POPULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GENOTYPE; HUMANS; INCIDENCE; PHENOTYPE;

EID: 0034973622     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18603     Document Type: Article

References (78)

1. Consensus Statement. Management of dyslipidemia in adults with Diabetes
2. Aspirin therapy in diabetes
3. Current trials on angiotensin-converting enzyme inhibitors and endothelial dysfunction
4. Lipids and atherogenesis in diabetes mellitus
5. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production
6. Early abnormalities of cardiac function in noninsulin-dependent diabetes mellitus and impaired glucose tolerance
7. A randomised, blinded, trial of clopidogrel versus aspirin in patiuents at risk of ischaemic events (CAPRIE)
8. Meal-generated oxidative stress in type 2 diabetic patients
9. Post-meal coagulation activation in diabetes mellitus: The effect of acarbose
10. Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration
11. Vascular thrombosis in type 2 diabetes mellitus]
12. Post-challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program
13. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE- deficient Mice
14. The impact of cardiovascular disease on people with diabetes: The potential for prevention
15. Diabetic dyslipidaemia and coronary heart disease: New perspectives
16. Pleiotropic effects of statins
17. Genetherapy and cardiovascular disease
18. The pathogenesis of coronary artery disease and the acute coronary syndromes
19. Genetic markers to predict polygenic disease
20. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1 dependent mechanism. Implications for atherogenesis
21. Homocysteine and atherosclerosis
22. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup Analyses in the Cholesterol and Recurrent Events (CARE) Trial
23. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
24. Diabetes and decline in heart disease mortality in US adults
25. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
26. Insulin resistant prediabetic subjects have more atherogenic risk factors than insulinsensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state
27. Inflammation and immune response in atherosclerosis
28. Functional genomics and DNA array techniques in atherosclerosis research
29. Insufficient glycemic control increases NFκB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes
30. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
31. Diabetes mellitus: A major risk factor for cardiovascular disease
32. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients
33. Cardiovascular disease and its risk factors in IDDM in Europe
34. Protein kinase C activation and the development of diabetic complications
35. Dependent diabetes mellitus
36. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion
37. Platelet glyco-protein IIb/IIIa receptors in cardiovascular medicine
38. Platelet Fibrinogen Receptor PIA1/A2 Polymorphism: A Candidate Gene for Vascular Complications in type 2 Diabetes
39. Non-invasive assessment of cardiovascular disease in diabetes mellitus
40. Flow-mediated dilation in 9-11 year old children
41. Novel inflammatory markers of coronary risk. Theory versus practice
42. Endothelial dysfunction in type 1 diabetic subjects with and without microalbuminuria
43. Inflammation, infection and atherosclerosis
44. Platelet GPIIIa PIA polymorphisms display different sensitivity to agonists
45. Risk factors for coronary heart disease and acute phase proteins. A population based study
46. Impairment of coronary vascular reserve and ACH-induced coronary vasodilatation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function
47. Susceptibility mutations for ischemic heart disease
48. Hypercholesterolemia increases endothelial superoxide anion production
49. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infacrtion in the Finnish Population
50. Antiplatelet agents in the prevention of diabetic vascular complications
51. A review of alterations in endothelial nitric oxide production in diabetes. Protective role of arginine on endothelial dysfunction
52. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
53. Leukocyte-platelet co-aggregation Hallmarks the severity of diabetic microangiopathy
54. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
55. Long-Term effects of pravastatin on plasma voncentration of Creactive protein
56. Endothelial relaxation is disturbed by oxidative stress in the diabetic heart: The influence of tocopherol as antioxidant
57. Vascular complications in diabetes: Mechanisms and the influence of antioxidants
58. Atherosclerosis- An inflammatory disease
59. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
60. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia
61. Reduced binding of anti-fibrinogen-receptor-beta 3 subunit (CD61) monoclonal antibody SZ21 indicates altered receptor phenotype in PIX/A 2 genotype patients with Diabetes mellitus
62. Impaired coronary flow reserve in NIDDM: A possible role for diabetic cardiopathy in humans
63. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy
64. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
65. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
66. Endotheliopathy precedes type 2 diabetes
67. Inflammation markers and coronary heart disease
68. Platelet-leukocyte cross-talk in diabetes mellitus
69. Heart disease in diabetes mellitus: A challenge for early diagnosis and intervention
70. Platelet Flow Cytometry- Adhesion Molecules
71. Diabetes mellitus und das Gerinnungssystem
72. Klinische Anwendung von GpIIbIIIa Antagonisten- Perspektiven für die Langzeitprophylaxe
73. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia
74. Overview of 6 years' therapy of type II diabetes: A progressive disease
75. The PIA2 polymorphism of integrin ß3 enhances outside-in signaling and adhesive functions
76. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality
77. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
78. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects